December 4, 2021 10:22am
A mixed week of November leaving and December beginning.
As we end November with one (1) negative and one (1) positive session while the first three (3) sessions of December exhibited two (2) negative closes and one (1) positive.
Sector equities are not easy to buy in this environment as …
- November ended with 1 holiday 5 positive and 16 negative close to date
Key metric this week; The CBOE volatility index, the VIX fear gauge, was higher 30.96 after Thursday’s 27.95 after Wednesday’s 31.12, Tuesday’s 27.19 and Monday’s 22.96.
Key factors: “The uncertainty regarding Omicron is high, but coupled with the disappointing jobs number and investors decided to dump (shares) in front of the weekend.” <read more>
Composite of comments: not to bore with all of them…
Let’s NOT forget that the stem, cell and gene therapy sector has been showing some strain for many weeks.
I stated, “I don’t feel the term “rally is to describe the sector’s move; it was an oversold response – just another rebound!”
- Another way to expound, the sector recovered ground lost over recent past sessions as the algorithms instructed and re-ruled there were bargains … ignoring the implications of a shifting pandemic – it’s not programmed-in.
The advance/decline lines deteriorated through-out November even as the Nasdaq kept hitting new highs.
We are also about to enter into TAX SELLING for year’s end!
In any case, I wouldn’t ramp up your exposure at the current levels.
There's also nothing wrong with standing pat after reducing exposure earlier in the month.
Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”
I don’t believe the market and sector conditions are favorable in the very short-term. The risk of market-shaking headlines is very high, at least until there's greater understanding of the omicron variant, and what that might mean for the economy.
The week …
RegMed Investors’ (RMi) pre-open: will futures moves drive a sustainable sector response … https://www.regmedinvestors.com/articles/12201
RegMed Investors’ (RMi) closing bell: Monday wasn’t quite the cell and gene therapy sector opportunity as I had questioned, what was sustainable? … https://www.regmedinvestors.com/articles/12202
RegMed Investors’ (RMi) pre-open: it ain’t over, investors are wary of buying dips as electronic trading contracts and controls share pricing … https://www.regmedinvestors.com/articles/12203
RegMed Investors’ (RMi) closing bell: a sector positive close to close the month … https://www.regmedinvestors.com/articles/12204
RegMed Investors’ (RMi) pre-open: what went down, does come back up … https://www.regmedinvestors.com/articles/12205
RegMed Investors’ (RMi) closing bell: snap, crackle and drop … https://www.regmedinvestors.com/articles/12206
RegMed Investors’ (RMi) pre-open: bounce-back … https://www.regmedinvestors.com/articles/12207
RegMed Investors’ (RMi) closing bell: finding its footing in an up sector … https://www.regmedinvestors.com/articles/12208
RegMed Investors’ (RMi) pre-open: a pre-occupied week … https://www.regmedinvestors.com/articles/12209
RegMed Investors’ (RMi) closing bell: the “Limbo Dance” how low can we go? … https://www.regmedinvestors.com/articles/12210
To end, I stated: The end of a roller-coaster week driven by Covid omicron variant developments and today’s disappointing November jobs report.
Also with someone else’s quote, “The uncertainty regarding Omicron is high, but coupled with the disappointing jobs number and investors decided to dump in front of the weekend,” said Ryan Detrick, chief market strategist at LPL Financial.
RMi is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What
RMi is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up ...
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.